Human peroxisome proliferator-activated receptor gamma (hPPARγ) has been implicated in numerous pathologies, including obesity, diabetes, and cancer. In this study, we verified that amentoflavone is an agonist of hPPARγ and probed the molecular basis of its action. It was demonstrated that amentoflavone bound hPPARγ with high (picomolar) affinity and increased the binding between hPPARγ and steroid receptor coactivator-1 (SRC-1) by approximately 4-fold. Based on a docking study, for the first time, we propose a model of amentoflavone and hPPARγ binding in which amentoflavone forms three hydrogen bonds with the side chains of His323, Tyr327, and Arg280 in hPPARγ and participates in two hydrophobic interactions.
Introduction
Nuclear receptors (NRs) are ligand-activated transcription factors that are responsible for sensing hormones and other molecules.
1,2 NRs regulate the expression of specific genes that control homeostasis and the metabolism of organs in response to steroid and thyroid hormones and other ligands. One of the most well known NR subfamilies is the peroxisome proliferator-activated receptors (PPARs). PPARs play central roles in regulating cellular differentiation, development, and tumorigenesis. Therefore, PPARs are noteworthy therapeutic targets for several metabolic disorders such as obesity, type-2 diabetes, and cancer. [3] [4] [5] [6] PPARs are activated by natural ligands, including fatty acids and cholesterol metabolites.
7 Activated PPARs form a heterodimeric complex with retinoid-X receptors (RXRs) that recruits coactivators to promoter regions of genes involved in the control of lipid metabolism, and thereby regulates their transcription.
8,9
Three PPAR isoforms−PPARα, PPARγ, and PPARδ− which share over 60% sequence homology in their ligandbinding domains (LBDs) and DNA-binding domains, have been identified in humans. 7 The structures of PPARs and their therapeutic and biological actions have been studied in detail since their initial discovery. PPARγ, the most wellknown PPAR, is present in adipocytes in high concentrations. Because it is highly expressed in adipocytes, PPARγ has long been considered a typical therapeutic target for type-2 diabetes. However, another function of PPARγ is to regulate cellular proliferation, differentiation, and apoptosis. PPARγ's effects on apoptosis and cell differentiation are beneficial in chemotherapy against a number of human cancers, including lung, breast, colon, cervical, and prostate cancers.
10-12
Because of its attractiveness as a therapeutic target in metabolic disorders and cancer, PPARγ has drawn considerable research attention over the last 15 years. Since the first report of the X-ray structure of the ligand-binding domain (LBD) of hPPARγ by Melburn et al. in 1999, 13 many other researchers have characterized hPPARγ three-dimensional structures using X-ray crystallography.
14,15 Thus far, this method has been used to establish the structures of hPPARγ in complex with agonists, designed using diverse methods. Xu et al. first determined the X-ray structure of hPPARγ and the representative agonist rosiglitazone in 2001, 16 and Willson et al. successfully designed an L-tyrosine analogue of the hPPARγ agonist GW409544. 17 Recent efforts by a number of research groups, including those of Sahoo 18 and Henke, 19 have focused on the design of novel agonists that exert dual agonistic activity on hPPARα and hPPARγ. Hibbs et al. also discovered a hPPARα/γ agonist from the flavonoid family. 20 These dual agonists have led to improved therapeutic effects in PPAR-related diseases, including type-2 diabetes and metabolic disorders.
The ligands of PPARγ are diverse and include thiazolidinediones (TZDs), polyunsaturated fatty acids, and nonsteroidal anti-inflammatory drugs (NSAIDs). These ligands have high binding affinities for the LBD of PPARγ.
21,22
Indomethacin, an NSAID, is a representative PPARγ ligand that inhibits the growth of human colorectal cancer cells by directly activating PPARγ.
23
Flavonoids are popular natural products with a broad range of medicinal properties, including antioxidant, antiviral, antibacterial, and anticancer activities. 24, 25 Because they have low cytotoxicity in mammals, many flavonoids are used therapeutically. Flavonoids are agonists of NRs, and in this capacity act to inhibit the growth of tumors in various cancer cell types. [26] [27] [28] In our previous report, we identified and characterized a flavonoid activator of hPPARγ with cytotoxic activity. 29 Biflavonoids are a minor class of flavonoids, distributed in only a small number of plant families, that form homo-or heterodimers.
30,31 These dimeric structures are formed from many different combinations of flavonoids; to date, more than 200 biflavonoids with potential biological activities have been isolated. 32 Amentoflavone, a symmetric biflavonoid, is a homodimer of apigenins ( Figure 1 ) that has several known pharmacological activities. 30, 31 Amentoflavone has agonist activity toward hPPARγ, but the mechanism underlying this activity is unclear. 33, 34 Here, to verify amentoflavone as an agonist of hPPARγ and probe the molecular basis of its action, we propose a binding model of amentoflavone and hPPARγ.
Methods
Extraction and Isolation of Amentoflavone. The whole plant of Selaginella tamariscina (600 g) was extracted with MeOH at room temperature yielding 50.54 g of residue. The methanol extract was re-suspended in water and partitioned sequentially with dichloromethane, ethyl acetate, and nbutanol. The EtOAc fraction (3.0 g) was placed a silica gel (300 g, 4.8 × 45 cm) column and eluted using a CHCl 3 -MeOH-H 2 O (12:1:0.1 → 8:1:0.1 → 5:1:0.1 → 2:1:0.1 → 1:1:0.1 → MeOH only) gradient system. Based on their TLC pattern, the fractions were combined to yield subfractions, which were designated E1-10. Subfraction E7 (296.33 mg) was finally purified by repeated column chromatography over a silica gel, RP-18, and Sephadex LH 20, yielding amentoflavone (82.23 mg). The UV, 1 H NMR, and 13 C NMR data for amentoflavone were identical to those reported in the literature.
35,36
Expression and Purification of hPPARγ. A hexahistidine-tagged hPPARγ expression vector, pET-28a-hPPARγ-His, was constructed by cloning into the BamHI/XhoI restriction sites, and transformed into the Escherichia coli strain BL21. To acquire the recombinant protein, transformed bacteria cultured in LB media were treated with 1 mM IPTG at OD 600 0.4-0.6 and induced overnight at 20°C. After harvesting, the cells were resuspended in buffer comprising 20 mM HEPES (pH 7.4), 250 mM NaCl, and 50 mM imidazole. The cell lysate was centrifuged, and the supernatant was loaded onto a HiTrap chelating column (GE Healthcare) that had been pre-equilibrated with buffer A (20 mM HEPES (pH 7.4) and 10% glycerol). The column was washed with buffer A, and then, the bound material was eluted with a linear gradient of 0-500 mM imidazole. The hPPARγ-containing fractions were loaded onto a Superdex 75 column (GE Healthcare) pre-equilibrated with buffer B (10 mM Tris (pH 8.0), 0.5 mM EDTA, 50 mM NaCl, and 10 mM β-mercaptoethanol).
A Simple Method to Screen PPARγ Ligands. In brief, amentoflavone was diluted in a bacterial cell lysate containing His-tagged human PPARγ and the mixture was added to 96-well plates pre-coated with SRC-1 recombinant protein. After incubation for 1 h, the wells were washed 3 times with phosphate-buffered saline containing 0.05% Tween 20 (PBST), before incubation with monoclonal anti-PPARγ antibody (Pγ48.34A) in 5% skim milk for 1 h. After washing 3 times with PBST, horseradish peroxidase (HRP)-conjugated anti-mouse IgG in 5% skim milk was added to the wells and further incubated for 1 h. After the plates were washed, SureBlue TMB Microwell Peroxidase Substrate (KPL, Inc. Gaithersburg, MD) was added, and the enzyme reaction was stopped by adding 2.5 N sulfuric acid. Enzyme activity was detected at 450 nm using an ELISA reader (Apollo LB 9110, Berthold Technologies GmbH, Germany).
Indomethacin, purchased from Sigma (St. Louis, MO), was used as a positive control and the anti-PPARγ monoclonal antibody (Pγ48.34A) was prepared as described previously.
37 Secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). All the other reagents used in this study were of analytical grade and obtained commercially.
Fluorescence-Quenching Experiments. Experiments were performed at 25 ºC on an RF-5301PC spectrofluorophotometer (Shimadzu, Kyoto, Japan). hPPARγ (5 μM) was dissolved in buffer B. Amentoflavone was titrated to give a protein:ligand molar ratio of 1:10. The sample was measured in a 2 mL thermostatted cuvette with excitation and emission path lengths of 10 mm. Samples were excited at 280 nm, and the emission spectra were recorded for light-scattering effects from 260 nm to 600 nm. We estimated K d according to the Stern-Volmer equation.
38
Docking Study. To determine the binding model between amentoflavone and hPPARγ, we performed an automated docking. In our previous report, we performed virtual screening for hPPARγ ligands, using the two x-ray structures that form a complex model with hPPARγ and its agonists, rosiglitazone and GW40954. 17 On the basis of electrostatic and hydrophobic interactions in the x-ray structures, we defined the active site that includes two or three hydrogen bonds with His323 in helix 5, Tyr327 in helix 3, and His449 in helix 10 of hPPARγ. X-ray structure of hPPARγ (2PRG. pdb) was used for this study. 13 Computations were performed on a Linux platform using DS modeling/CDOCKER (Accelrys Inc., San Diego, USA) with the CHARMM force field.
39-41
Results and Discussion PPARγ Agonist Activity. Using a simple ELISA-based ligand-screening system, we observed binding between PPARγ and SRC-1 in the presence of candidate ligands. If a ligand is proper agonist of PPARγ, the expression of PPARγ would be stimulated and the binding between PPARγ and SRC-1 would increase. Indomethacin, which is an effective, low-cost alternative to TZD, was used as a positive control. As shown in Figure 2 , amentoflavone induced a concentration-dependent increase in the binding between purified PPARγ and SRC-1, promoting a degree of binding that was approximately 3−4-fold higher than that in the absence of ligand and up to 20% of that produced by indomethacin (80 mM). Thus, although amentoflavone is less effective than indomethacin in increasing the level of activated hPPARγ, it clearly increased binding between hPPARγ and SRC-1 and thus can be considered to act as an agonist of hPPARγ.
Binding Assay Using Fluorescence Quenching. We used fluorescence quenching experiments to determine the dissociation constant (K d ) of amentoflavone and indomethacin with respect to interaction with hPPARγ. Fluorescence curves of amentoflavone and indomethacin in the presence of hPPARγ are depicted in Figure 3 . Amentoflavone bound strongly to hPPARγ, with a dissociation constant in the picomolar range. Notably, with a K d on the order of 10 , respectively. These data indicate that amentoflavone is a possible hPPARγ agonist that binds with high affinity.
Binding Model of PPARγ and Amentoflavone. Amentoflavone is a naturally occurring symmetric biflavone that forms a homodimer of apigenins (also called 5',8''-biflavone). The 5'-carbon of the B-ring and the 8''-carbon of the D-ring form a covalent bond. Amentoflavone has several known pharmacological activities, including anti-inflammatory, antioxidative, and anticancer effects.
The binding model of a known inhibitor, indomethacin, and hPPARγ is proved by x-ray crystallography. 42 The ligand binding site of LBD of PPARγ has two sub-pockets on the center of Helix 3 (H3) (Figure 4(a) ); One pocket is included H12 and another is located on H5 region. Whereas the full agonists occupy these two pockets, the partial agonists bind to only one pocket on H5. 42 In the case of a full agonist indomethacin, two indomethacin molecules bind to LBD. Two carboxyl groups of indole acetate moiety in indomethacin form hydrogen bonding interactions with His 323 on the H4 and Tyr473 on the H12 of hPPARγ. It is know that this pocket is crucial role to full agonist activity of hPPARγ and some hydrogen bonding interactions are included. Other molecule in second pocket forms only hydrophobic interaction with several residues, such as Val330, Leu340, and Ile341. The binding model between indomethacin and hPPARγ is shown in Figure 4(b) .
We conducted a docking simulation to characterize the binding of hPPARγ and amentoflavone. According to the resulting docking model, amentoflavone occupied two known sub-pockets. It formed three hydrogen bonds and two hydrophobic interactions with hPPARγ at the ligand-binding site. The 5'-hydroxyl group of the D-ring and the carbonyl oxygen of the F-ring of amentoflavone participated in hydrogen bonds with the side chain of His323 and Tyr327 of hPPARγ. These hydrogen-bonding interactions are highly conserved in most agonists of hPPARγ and are also essential for the activity of hPPARγ. The 5'-hydroxyl group of the Aring formed two hydrogen bonds with the side chain of Arg280 in H3. The E-ring of amentoflavone formed a hydrophobic interaction with three aromatic residues, namely Phe282, Phe360, and Phe363. This hydrophobic pocket presents at the H3 and the H7 region of hPPARγ. The second hydrophobic interaction was formed between the aliphatic hydrophobic residues Ile281, Val339, Ile341 and Met367 of hPPARγ, and the B-ring of amentoflavone. As compared with the binding model of indomethacin, amentoflavone formed more hydrogen bonding interactions and specific hydrophobic interactions with PPARγ. Therefore the three hydrogen bonds and two hydrophobic interactions contributed to the strong binding of amentoflavone to hPPARγ. Specific interactions are depicted in Figure 4 (c).
Conclusion
Taken together, amentoflavone increased the binding between hPPARγ and steroid receptor coactivator-1 (SRC-1) by approximately 4-fold and showed higher binding affinity to hPPARγ at picomolar concentrations. We determined the binding model of amentoflavone and hPPARγ for the first time. They formed three hydrogen bonds and two hydrophobic interactions and these interactions contributed to the strong binding of amentoflavone to hPPAR. Further research will be carried out to investigate the anticancer mechanisms of amentoflavone. 
